• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Postpartum cerebral venous sinus thrombosis following obstetric neuraxial blockade: a literature review with analysis of 58 case reports
Cerebral venous sinus thrombosis (CVST) is an uncommon but serious complication of pregnancy.1 Pooled analysis from a recent systematic review revealed that CVST is one of the major causes of stroke in pregnancy.2 Confidential maternal death enquiry reports in the United Kingdom (UK) have identified 12 deaths from CVST across the last 15 years.3 –5 The postpartum period, especially the first six weeks following delivery, is now considered an independent risk factor for CVST, with the risk 3.5 times higher when compared with non-pregnant women.
Source: International Journal of Obstetric Anesthesia - September 15, 2021 Category: Anesthesiology Authors: D.J. Chambers, K. Bhatia, M. Columb Tags: Review Article Source Type: research